Core Insights - Strata Critical Medical, Inc. reported a revenue increase of 36.7% year-over-year to $49.3 million for Q3 2025, with organic growth of 29.0% excluding the Keystone acquisition [4][6] - The company experienced a net loss from continuing operations of $(9.7) million, an increase from $(5.6) million in the prior year [4][6] - Adjusted EBITDA for the Medical Segment rose by 93.5% to $7.6 million, reflecting strong operational performance [4][6] Financial Results - Total revenue for Q3 2025 was $49,298 thousand, compared to $36,062 thousand in Q3 2024, marking a 36.7% increase [2] - Cost of revenue increased by 32.0% to $37,684 thousand in Q3 2025 from $28,554 thousand in Q3 2024 [2] - Gross profit for Q3 2025 was $9,545 thousand, up from $5,427 thousand in the prior year, resulting in a gross margin of 19.4% [2][6] Operating Expenses - Total operating expenses increased by 27.3% to $54,920 thousand in Q3 2025 from $43,154 thousand in Q3 2024 [2] - General and administrative expenses rose by 17.5% to $16,301 thousand in Q3 2025 [2] - Selling and marketing expenses increased significantly by 53.5% to $482 thousand [2] Adjusted Metrics - Adjusted EBITDA for Q3 2025 was $4,214 thousand, a substantial increase from $67 thousand in Q3 2024 [3][4] - Medical Segment Adjusted EBITDA margin improved to 15.3% in Q3 2025 from 10.8% in Q3 2024 [5][6] - Flight Profit increased by 54.7% to $11,614 thousand, with a Flight Margin of 23.6% [3][6] Business Developments - The company raised its 2025 revenue guidance to $185-195 million, up from the previous range of $180-190 million [4][14] - Strata completed the divestiture of its Passenger business and the acquisition of Keystone Perfusion, positioning itself for long-term growth [4][14] - The integration of Keystone is reported to be progressing well, with a focus on operational efficiencies [4][6] Cash Flow and Capital Expenditures - Operating cash flow was $(37.3) million in Q3 2025, influenced by acquisition-related payments [6] - Capital expenditures for the quarter were $3.2 million, primarily for aircraft maintenance [6][13] - The company ended Q3 2025 with $75.9 million in cash and short-term investments [13]

Company Overview - Strata Critical Medical, Inc. is a time-critical logistics and medical services provider to the U.S. healthcare industry, operating one of the largest air transport and surgical services networks for transplant hospitals and organ procurement organizations [3][4] - The company offers an integrated "one call" solution for donor organ recovery, which includes air and ground logistics, surgical organ recovery, organ placement, and normothermic regional perfusion for the transplant industry [4] Upcoming Event - Strata will hold an Investor Day at the Nasdaq MarketSite in New York City on November 17th, 2025, starting at 2:00 PM ET, featuring presentations by the management team [1] - Investors and analysts can register for the event on Strata's Investor Relations website, with a live video webcast and presentation materials available on the day of the event [2]